NCT01711164View on ClinicalTrials.gov

The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis

CompletedOBSERVATIONAL
Enrollment

106

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

September 30, 2016

Conditions
Chronic Hepatitis C Infection
Trial Locations (1)

M4G 2C4

University Health Network, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT01711164 - The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis | Biotech Hunter | Biotech Hunter